Crossmark

Complicated regulatory decision-making following inconsistent trial results: the issue with ibrutinib for mantle cell lymphoma

Published Online: 2023-09-21

Published Print: 2024-01

Authors

Cliff, Edward R. Scheffer https://orcid.org/0000-0001-5977-907X
Hilal, Talal https://orcid.org/0000-0001-8249-4128
Kesselheim, Aaron S.
License Information

Text and Data Mining valid from 2023-09-21

Version of Record valid from 2023-09-21
More Information

Article History

First Online: 21 September 2023

Competing interests

: A.S.K. reports having served as an expert witness on behalf of the Leukemia and Lymphoma Society in litigation relating to royalties on venetoclax (2021–2022). E.R.S.C. and T.H. have no competing interests to declare.

Document is current